Summary
IDEXX Laboratories, Inc. reported solid financial results for the first quarter of 2024, with total revenue reaching $964.1 million, a 7.1% increase year-over-year. This growth was primarily driven by its core Companion Animal Group (CAG) segment, which saw a 7.5% revenue increase, largely due to higher recurring revenue from diagnostics, consumables, and veterinary software and services. The company also demonstrated improved profitability, with gross profit rising 9.2% and income from operations increasing 6.6% to $299 million, reflecting an expanded gross margin of 61.5% compared to 60.3% in the prior year, aided by favorable sales mix and pricing. While the company continues to invest in growth, evidenced by a rise in R&D and G&A expenses, its financial position remains strong. Net income increased by 10.1% to $235.6 million, resulting in diluted EPS of $2.81, up from $2.55 in the prior year. The company also maintained a healthy liquidity position, with $397.4 million in cash and cash equivalents and significant borrowing availability under its credit facility. Notably, IDEXX repurchased $154.8 million of its common stock during the quarter, signaling confidence and a commitment to returning value to shareholders. The company expects continued growth, though it acknowledges potential headwinds from macroeconomic conditions and foreign currency fluctuations.
Financial Highlights
54 data points| Revenue | $964.10M |
| Cost of Revenue | $371.02M |
| Gross Profit | $593.07M |
| R&D Expenses | $52.63M |
| Operating Expenses | $294.11M |
| Operating Income | $298.96M |
| Interest Expense | $7.91M |
| Net Income | $235.58M |
| EPS (Basic) | $2.84 |
| EPS (Diluted) | $2.81 |
| Shares Outstanding (Basic) | 83.10M |
| Shares Outstanding (Diluted) | 83.96M |
Key Highlights
- 1Total revenue increased by 7.1% year-over-year to $964.1 million, primarily driven by the Companion Animal Group (CAG).
- 2CAG segment revenue grew 7.5% to $889.3 million, fueled by recurring revenue from diagnostics and veterinary software/services.
- 3Gross profit increased by 9.2% to $593.1 million, with gross margin expanding to 61.5% from 60.3% in the prior year.
- 4Net income rose by 10.1% to $235.6 million, and diluted earnings per share (EPS) improved to $2.81 from $2.55 year-over-year.
- 5Operating expenses saw an increase, particularly in General and Administrative (G&A) and Research and Development (R&D), impacting operating income growth to 6.6%.
- 6The company repurchased $154.8 million of its common stock during the quarter.
- 7IDEXX maintained a strong liquidity position with $397.4 million in cash and cash equivalents and $998.5 million in available borrowing capacity under its credit facility.